Developing new treatments and vaccines for Valley Fever.
Official title: SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.
Funded at University of Texas San Antonio · NIH-11004646 · Data updated 2026-11-12
This study is working to find better treatments and vaccines for Valley Fever, a condition that affects many people in the Southwest U.S., and aims to help patients by bringing together experts to create new and effective options for managing the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas San Antonio NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,357,000 |
| NIH project number | 5U19AI166761-04 |
| Project ID | NIH-11004646 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living in endemic areas who are at risk of or currently suffering from Coccidioidomycosis.
✕Less likely to help
Patients who do not reside in endemic regions or those with conditions unrelated to Coccidioidomycosis may not benefit from this research.
What this research studies
This research focuses on Coccidioidomycosis, commonly known as Valley Fever, which affects many individuals in the arid regions of the Southwest U.S., particularly California and Arizona. The project aims to establish a collaborative research center in San Antonio to develop effective antifungal drugs and vaccines, addressing the urgent need for better treatment options due to rising antibiotic resistance. The research will involve a multidisciplinary approach, bringing together experts from various fields to enhance the understanding and management of this disease. Patients may benefit from innovative therapies that could significantly improve their health outcomes.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antifungal treatments and vaccines for Valley Fever, improving patient care and outcomes.
How similar studies have gone: While there has been limited success in developing treatments for Coccidioidomycosis, this research represents a novel and comprehensive approach to tackling the disease.
Where this research is happening
-
University of Texas San Antonio
San Antonio, United States Active
Researchers
- Principal investigator: Hung, Chiung-Yu — University of Texas San Antonio
- Study coordinator: Hung, Chiung-Yu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.